CD274 and non-small cell lung carcinoma: Blood-based biomarkers for prediction and surveillance of immunotherapy response in NSCLC are an active field of research due to ease of sampling as compared to tissue biopsies, and several potential biomarkers, including different forms of PD-L1, non-coding RNAs, immune cells, peripheral cytokines, circulating free DNA, and tumor mutational burden, have recently emerged (as reviewed in [12]).